Edition:
India

Ardelyx Receives FDA Approval For Ibsrela® (Tenapanor), An Nhe3 Sodium Transport Inhibitor, For The Treatment Of Irritable Bowel Syndrome With Constipation


Friday, 13 Sep 2019 

Ardelyx Inc ::ARDELYX RECEIVES FDA APPROVAL FOR IBSRELA® (TENAPANOR), AN NHE3 SODIUM TRANSPORT INHIBITOR, FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION.ARDELYX INC - CO IS "WELL POSITIONED" TO FILE NDA FOR HYPERPHOSPHATEMIA NEXT YEAR WITH POTENTIAL APPROVAL AND LAUNCH IN 2021. 

Company Quote

6.14
-0.01 -0.16%
15 Nov 2019